- Home
- CRVO vs CLSD Comparison
CRVO vs CLSD Comparison
Compare CRVO & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- CLSD
- Stock Information
- Founded
- CRVO 2001
- CLSD 2011
- Country
- CRVO United States
- CLSD United States
- Employees
- CRVO N/A
- CLSD N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- CLSD Health Care
- Exchange
- CRVO Nasdaq
- CLSD Nasdaq
- Market Cap
- CRVO 67.4M
- CLSD 68.4M
- IPO Year
- CRVO N/A
- CLSD 2016
- Fundamental
- Price
- CRVO $10.12
- CLSD $0.42
- Analyst Decision
- CRVO Strong Buy
- CLSD Hold
- Analyst Count
- CRVO 6
- CLSD 4
- Target Price
- CRVO $17.60
- CLSD $4.33
- AVG Volume (30 Days)
- CRVO 820.1K
- CLSD 12.9M
- Earning Date
- CRVO 08-08-2025
- CLSD 08-08-2025
- Dividend Yield
- CRVO N/A
- CLSD N/A
- EPS Growth
- CRVO N/A
- CLSD N/A
- EPS
- CRVO N/A
- CLSD N/A
- Revenue
- CRVO $7,776,968.00
- CLSD $4,166,000.00
- Revenue This Year
- CRVO N/A
- CLSD $78.37
- Revenue Next Year
- CRVO N/A
- CLSD $17.79
- P/E Ratio
- CRVO N/A
- CLSD N/A
- Revenue Growth
- CRVO N/A
- CLSD N/A
- 52 Week Low
- CRVO $1.80
- CLSD $0.29
- 52 Week High
- CRVO $20.63
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- CRVO 65.00
- CLSD 39.95
- Support Level
- CRVO $9.11
- CLSD $0.40
- Resistance Level
- CRVO $9.96
- CLSD $0.47
- Average True Range (ATR)
- CRVO 0.79
- CLSD 0.06
- MACD
- CRVO 0.06
- CLSD 0.01
- Stochastic Oscillator
- CRVO 90.31
- CLSD 26.87
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.